Beta Bionics (NASDAQ:BBNX) Insider Sells $30,073.50 in Stock

by · The Cerbat Gem

Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) insider Steven Jon Russell sold 1,025 shares of Beta Bionics stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $29.34, for a total value of $30,073.50. Following the transaction, the insider owned 178,071 shares in the company, valued at $5,224,603.14. This trade represents a 0.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Steven Jon Russell also recently made the following trade(s):

  • On Monday, March 2nd, Steven Jon Russell sold 1,026 shares of Beta Bionics stock. The stock was sold at an average price of $12.36, for a total value of $12,681.36.

Beta Bionics Stock Performance

BBNX stock traded up $0.48 during mid-day trading on Monday, hitting $10.87. 911,515 shares of the company were exchanged, compared to its average volume of 1,199,208. Beta Bionics, Inc. has a 1-year low of $8.89 and a 1-year high of $32.71. The firm’s 50 day simple moving average is $15.15 and its 200 day simple moving average is $22.01.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.12. The company had revenue of $32.12 million during the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Institutional Trading of Beta Bionics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its position in shares of Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after buying an additional 1,818 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Beta Bionics by 140.9% during the 4th quarter. Invesco Ltd. now owns 117,360 shares of the company’s stock worth $3,576,000 after acquiring an additional 68,640 shares during the last quarter. XTX Topco Ltd bought a new stake in Beta Bionics in the 4th quarter valued at $1,340,000. Voloridge Investment Management LLC lifted its holdings in Beta Bionics by 549.6% during the 4th quarter. Voloridge Investment Management LLC now owns 151,647 shares of the company’s stock valued at $4,621,000 after purchasing an additional 128,301 shares during the last quarter. Finally, Tudor Investment Corp ET AL lifted its holdings in Beta Bionics by 572.7% during the 4th quarter. Tudor Investment Corp ET AL now owns 259,632 shares of the company’s stock valued at $7,911,000 after purchasing an additional 221,039 shares during the last quarter.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on BBNX shares. Truist Financial dropped their target price on Beta Bionics from $37.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beta Bionics in a research report on Monday, December 29th. Stifel Nicolaus lowered their price objective on shares of Beta Bionics from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday, February 18th. UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a research report on Monday, February 9th. Finally, Bank of America cut shares of Beta Bionics from a “buy” rating to a “neutral” rating in a report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.20.

Check Out Our Latest Stock Report on Beta Bionics

About Beta Bionics

(Get Free Report)

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.

Recommended Stories